The Advances in PSA-Based Screening for Early Detection of Prostate Cancer

Abstract

Prostate‑specific antigen (PSA) testing has long been the cornerstone of prostate cancer screening, significantly improving the early detection of prostate malignancies; however, its limited specificity and risk of overdiagnosis remain major clinical challenges. Traditional PSA assays do not distinguish between benign prostatic conditions and clinically significant cancer, resulting in unnecessary biopsies and overtreatment. Recent advances in PSA‑based screening have sought to refine risk stratification and improve diagnostic accuracy. These refinements include age‑adjusted PSA thresholds, PSA density, and PSA velocity, which take into account a patient’s age, prostate volume, and longitudinal PSA dynamics to better interpret PSA levels in context.Furthermore, the incorporation of PSA derivatives and isoforms—such as free PSA, complexed PSA, and pro‑PSA—enables more nuanced screening. In particular, tests like the prostate health index (PHI), combining total PSA, free PSA, and [−2] pro‑PSA, have demonstrated improved specificity and greater discrimination of aggressive disease. Additional blood‑based kallikrein panels such as the 4K score (which includes total PSA, free PSA, intact PSA, and kallikrein‑related peptidase 2) further enhance risk stratification by estimating the probability of high‑grade prostate cancer. Moreover, emerging biomarkers derived from urine (e.g., PCA3, TMPRSS2‑ERG) offer non‑invasive adjuncts to PSA testing, reducing unnecessary biopsies while preserving sensitivity for clinically relevant disease.Parallel to biomarker innovation, advances in imaging—especially multiparametric MRI—and artificial intelligence (AI) methods are being integrated into screening pathways to further refine detection. AI‑driven algorithms can interpret imaging data and combine molecular, clinical, and imaging features to guide biopsy decisions more accurately. Together, these novel PSA‑based approaches—multimodal biomarkers, refined algorithms, and imaging synergy—are transforming prostate cancer screening toward more personalized, risk‑adapted strategies. Adoption of these advances could reduce overdiagnosis, minimize harms, and improve the early detection of clinically significant prostate cancer, though continued validation in large, diverse populations is needed.